Lupin receives US FDA warnings at two Indian manufacturing plants

By Dan Stanton

- Last updated on GMT


Related tags Food and drug administration Federal food drug and cosmetic act

Indian drugmaker Lupin says product supply will not be disrupted at plants in Goa and Indore hit with a combined US FDA warning letter.

In a filing​ with the Bombay Stock Exchange Tuesday, Lupin said it has received a US Food and Drug Administration (FDA) warning letter on November 6 concerning its formulation facilities in Goa and Indore (Pithampur unit II).

“We had earlier received three Form 483 observations in Goa on April 7, 2017 and six Form 483 observation in Pithampur (Unit II) on May 19, 2017,”​ the firm said. “We had responded to all the observations.”

Details of the observations and subsequent GMP violations were not divulged.

“We are deeply disappointed to have received this outcome. While there will be no disruption of existing products supplies from either of these locations, there will likely be a delay of new product approvals from these two facilities,”​ Lupin said.

Lupin's stock hit a three year low, falling 15% following the announcement.

The Goa plant, which makes finished drug formulations – including oral and injectable drug products – for the US market, has been subject to previous FDA criticism, including nine observations “on aspects such as inadequacy and adherence to SOPs”​ following an inspection in March 2016.

The facility received an establishment inspection report (EIR) nine months later​ clearing Lupin to supply the US with products made from the site.

Meanwhile Lupin’s manufacturing facility in Aurangabad received an FDA 483 in July this year​, citing a single observation. However, the firm said at the time this was “procedural in nature,”​ and that it had been corrected during the inspection.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us


View more